Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Thursday's Bonus News Guardian Pharmacy Stock Pops on Q3 Strength and Upbeat ForecastWritten by Ryan Hasson. Published 11/12/2025. 
Key Points - Guardian posted a standout Q3, with revenue up 20% year over year and EPS topping estimates.
- The company raised full-year guidance, reflecting growing demand and operational strength.
- Strong institutional inflows, high insider ownership, and a breakout above resistance suggest improving sentiment and potential upside.
Guardian Pharmacy Services Inc. (NYSE: GRDN), a small-cap healthcare company, made waves in Tuesday's session after reporting better-than-expected earnings that sent the stock surging on above-average volume. The $1.98 billion company, which had been consolidating in recent months, broke decisively higher following the results, capturing market attention and putting itself on the radar of both traders and long-term investors. Don't Leave Without Claiming Your $1 Black Friday Deal
Discover how AI can help you trade smarter. One dollar. No commitments. Unlock the Deal The key question now is whether this breakout marks the start of a larger move or is a short-term reaction to a strong quarterly report. A Leading Player in Long-Term Care Pharmacy Services Guardian Pharmacy Services focuses on supporting residents of long-term care facilities (LTCFs) across the United States. The company provides technology-driven pharmacy management solutions designed to simplify medication handling, improve adherence, and enhance overall health outcomes. Its services reach assisted living facilities, skilled nursing centers, group homes, behavioral health institutions, and organizations serving individuals with intellectual and developmental disabilities. Guardian's mission centers on promoting health and wellness for older adults and people with complex care needs while easing operational burdens for caregivers. Its tech-enabled approach aims to lower healthcare costs through improved medication efficiency and better patient outcomes. As of November 2025, Guardian operates a network of more than 53 pharmacies serving over 204,000 residents across 8,200 long-term care facilities in 38 states. The company's vision is to become the nation's leading provider of long-term care pharmacy services, supported by a passionate and diverse workforce. Q3 Earnings Top Expectations and Drive a Breakout The company's latest results beat expectations across the board. For the third quarter, Guardian reported revenue of $377 million, surpassing analyst estimates of $354 million. Earnings per share (EPS) came in at $0.25, $0.01 above consensus. Year-over-year revenue rose 20%, helped by a 13% increase in total residents served — a key growth metric that underscores expanding reach and demand for its pharmacy solutions. Guardian also raised its full-year guidance, reflecting confidence in continued momentum. The company now expects fiscal 2025 revenue of $1.43 billion to $1.45 billion, up from a prior range of $1.39 billion to $1.41 billion. Adjusted EBITDA is projected between $104 million and $106 million, versus the earlier $100 million to $102 million estimate. The higher outlook highlights management's confidence and suggests improving operational efficiency and sustained demand across its customer base. Key Ownership Trends to Watch While Tuesday's breakout was encouraging, several factors could shape sentiment and momentum in the months ahead. Chief among them are insider and institutional activity. Over the last 12 months, institutions have added approximately $142 million worth of shares, compared with about $41 million in outflows — a positive trend that points to growing interest from large investors. At the same time, insider selling has been notable: roughly $235 million was sold by seven insiders during the second quarter of 2025. Despite that selling, insider ownership remains very high at nearly 64%, which helps align leadership incentives with long-term shareholders. Monitoring future insider transactions and changes in institutional coverage will be important for gauging market confidence in the company's growth trajectory. Analyst coverage is limited, with just four analysts currently tracking the stock and rating it a Moderate Buy. Given the strong quarterly results and raised outlook, there is potential for upward revisions to price targets and for additional analyst coverage in the months ahead. A Compelling Small-Cap Healthcare Name to Watch Guardian Pharmacy Services may have been under the radar before this week, but that could be changing quickly. The company's strong Q3 performance, raised guidance, and expanding institutional interest point to growing recognition in the healthcare space. From a technical standpoint, maintaining support above $30 will be crucial for confirming the breakout and sustaining momentum. Investors should also weigh the risk of further insider selling and the limited analyst coverage when assessing the stock.
| 
Post a Comment
Post a Comment